TheraRadar
← Back
Data updated: Jun 28, 2026

ZHEJIANG NOVUS PHARM

Pharma

ZHEJIANG NOVUS PHARM is a pharmaceutical company focused on Infectious Disease, Dermatology.

2023
Since
2
Drugs
-
Trials
0
New Drugs (2yr)

ZHEJIANG NOVUS PHARM's Key Drugs

ZHEJIANG NOVUS PHARM's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).

No active drugs

ZHEJIANG NOVUS PHARM's Recent FDA Approvals

New NDA/BLA approvals for ZHEJIANG NOVUS PHARM over the last two years — novel drugs only, excluding generics and label supplements.

No recent approvals

ZHEJIANG NOVUS PHARM's Therapeutic Areas

ZHEJIANG NOVUS PHARM's approved drugs and pipeline span 2 therapeutic areas, led by Infectious Disease and Dermatology. Weighted by commercial stage — approved drugs count most, then late-stage trials.

Infectious Disease 67%
2 drugs
Dermatology 33%
1 drugs

ZHEJIANG NOVUS PHARM's Top Competitors

ZHEJIANG NOVUS PHARM's closest competitors by therapeutic-area and drug-target overlap include Pfizer, Baxter, and B BRAUN. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.

ZHEJIANG NOVUS PHARM Pipeline Snapshot

Active clinical trials for ZHEJIANG NOVUS PHARM across all therapeutic areas, from ClinicalTrials.gov.

No active pipeline data available

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • Top drug revenue breakdown
  • Drug-level revenue analysis

Trial Catalysts

  • Infectious Disease pipeline focus
  • Phase 3 readout tracking

Patent Risk

  • Patent expiration timeline
  • Revenue at risk analysis

Compare Companies

  • Side-by-side pipeline analysis
  • Revenue & market share comparison
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling